Samuel Isaly Says He Is Fond of Regeneron Pharmaceuticals Inc (REGN) & InterMune Inc (ITMN)

Samuel Isaly‘s Orbimed Advisors is one of the largest hedge funds focused almost entirely on the healthcare sector. In a recent intervention on CNBC, Mr. Isaly presented his bullish case on two stocks, which, surprisingly, aren’t among the top five holdings in Orbimed’s latest 13F. These companies are Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and InterMune Inc (NASDAQ:ITMN), both stocks of which experienced significant growth since the beginning of the year, while Intermune more than doubled within one day.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Mr. Isaly says that he finds this company the most attractive, mainly because of its “multi-billion dollar product for treatment of blindness in older people.” The product, called EYLEA® has recently been accepted by the FDA for the supplemental Biologics License Application for the treatment of Macular Edema Following Branch Retinal Vein Occlusion, the company said.  Moreover, Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin has filed an application for marketing authorization of the product with the Japanese Ministry of Health, Labour and Welfare, Regeneron said in another statement.

Isaly holds 738,800 shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN), according to Orbimed’s latest 13F filing. The reported value of the position amounts to over $203 million, which makes it the eight largest holding (3% of the equity portfolio). Orbimed has upped the position by 44% during the last quarter of 2013, and has been adding more shares to the holding over the past couple of years. Columbus Circle Investors, led by Donald Chiboucis, is also a shareholder of Regeneron, owning 410,800 shares. However, while Columbus inched down the holding, Jerome Pfund and Jerome Pfund Sectoral Asset Management, apparently aggree with Isaly, and boosted its holding by over 50% to 276,000.

Intermune

In InterMune Inc (NASDAQ:ITMN), Mr. Isaly surged its holding by some 170% and currently holds around 7.7 million shares. As it was mentioned above, this has been a great bet for Orbimed, as the stock of InterMune Inc (NASDAQ:ITMN) has managed to double since the beginning of the year, which values the holding at $242.5 million, at the current price. However, Mr. Isaly considers that this is not the stopping point for InterMune Inc (NASDAQ:ITMN) and that the stock price is poised to go even higher.

The explanation for this growth lie in the announcement made by InterMune Inc (NASDAQ:ITMN) at the end of February, which presented successful results from a Phase 3 trial of a drug called pirfenidone in patients with idiopathic pulmonary fibrosis. The drug managed to reduce the progression of the disease. In this way, the drug met the primary and secondary endpoints.

Aside from Orbimed, which owns one of the largest long positions in the company, William Leland Edwards‘ Palo Alto Investors also reported a stake in InterMune Inc (NASDAQ:ITMN), which amasses more than 3.8 million shares.

The full video of Mr. Isaly’s discussion on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Intermune can be watched below:

Disclosure: none

Recommended Reading:

Luxor Capital Group Raises Stake and Goes Activist on BJ’s Restaurants, Inc. (BJRI)

George Soros and Jeff Altman Are Both Betting On These Six Stocks

Warren Buffett and Lou Simpson Are Bullish On These Stocks

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!